Researchers found that 1,25(OH)2D3 treatment and vitamin D receptor agonist (VDRA) attenuated fibrosis and albuminuria in CKD patients by inactivating RAS, though vitamin D application has not been found to delay the progression of CKD [123]. The gene discussed is VDR; the disease is chronic kidney disease.